Cargando…
WITHDRAWN: COVID-19 Emergency Responders in FDA’s Center for Drug Evaluation and Research
The Publisher regrets that this article is an accidental duplication of an article that has already been published, https://doi.org/10.1016/j.japh.2020.04.007. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/...
Autores principales: | Gormley, LCDR Andrea, Ngan, CDR Kelly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc. on behalf of the American Pharmacists Association.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146656/ http://dx.doi.org/10.1016/j.japh.2020.04.007 |
Ejemplares similares
-
COVID-19 emergency responders in FDA’s Center for Drug Evaluation and Research
por: Gormley, Lieutenant Commander Andrea, et al.
Publicado: (2020) -
The effects of lobbying on the FDA’s recall classification
por: Zhou, Yifan
Publicado: (2023) -
The FDA’s Experience with Emerging Genomics Technologies—Past, Present, and Future
por: Xu, Joshua, et al.
Publicado: (2016) -
The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic
por: Diak, Ida-Lina, et al.
Publicado: (2022) -
Physician Perceptions of the FDA’s Breakthrough Therapy Designation: An Update
por: Paquin, Ryan S, et al.
Publicado: (2022)